Evogene (EVGN) Misses Q4 EPS by 20c

Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.28 million versus the consensus estimate of $650 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Goldman Sachs says Fed rate hike unlikely in September
• Shein targets $26-27 billion valuation in Hong Kong IPO - report